Web06. apr 2024. · Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates. Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 0% and … WebOncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript Motley Fool - Wed Aug 10, 4:30AM CDT . ONCT earnings call for the period ending June 30, 2024. ONCT: 1.0700 (-0.93%) Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates Zacks - Tue Aug 9, 6:05PM CDT .
Oncternal Therapeutics, Inc. (ONCT) Q4 2024 Earnings Call Transcript
Web21. mar 2024. · ONCT: Oncternal Therapeutics EPS. Get the latest EPS stock quote information from Zacks Investment Research. ... Oncternal Therapeutics, Inc. (ONCT) Q4 2024 Earnings Call Transcript 03/09/23-8 ... WebOncternal Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ONCT updated stock price target summary. the works teesside
Oncternal Therapeutics - ONCT News Today - MarketBeat
WebOncternal Therapeutic ONCT - Bullish bet This small-cap is a long-time leader in the oncology industry and has been highly rated by analysts in recent weeks. Oncternal … Web06. maj 2024. · On the cell therapy front, we are on track to submit our first IND for ONCT-808, our autologous ROR1 CAR-T cell candidate in mid-2024. For ONCT-534, our lead … Web10. apr 2024. · msn.com - August 10 at 2:29 PM. Oncternal Therapeutics, Inc.'s (ONCT) CEO Dr. James Breitmeyer on Q2 2024 Results - Earnings Call Transcript. seekingalpha.com - August 10 at 12:15 AM. Even after rising 16% this past week, Oncternal Therapeutics (NASDAQ:ONCT) shareholders are still down 73% over the … the works television station